Japan DNA Vaccine market is anticipated to grow at a CAGR 41.6% during the forecast period. Japan has the significant growth in the DNA Vaccine market due to increase in prevalence of chronic disease and health care infrastructure with development of new technology. Among major global economies, Japan has the highest percentage of geriatric population. Various cancers are more commonly found in elderly age group. For instance, colon cancer accounts for more than 90% of individuals diagnosed over the age of 50. Similarly, stomach cancer accounts for about 60% of those diagnosed are over the age of 60.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/japan-dna-vaccines-market
In Japan, the vaccination of the children is not mandatory however the government has provided the guidelines and recommendations regarding vaccination. The government has notified that it is the duty of the parents to immune their children from diseases. However, no penalty will be imposed on parents for not performing vaccination of their child.
The market is segmented on the basis of type, application and technology. Based on type, the market is segmented into animal DNA vaccine and human DNA vaccine. Based on technology, the market is segmented into plasmid DNA vaccine and plasmid DNA delivery. Based on application, the market is segmented into oncology, infectious disease and others.
The key market players that are active in the market include Asteel Pharma, Inc., Eli Lilly and Co., GE Healthcare, Glaxosmithkline PLC., Inovio Pharmaceuticals Inc., Merck & Co., Novartis AG, Pfizer Inc., Roche Diagnostics GMBH and Sanofi Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market. Moreover, Japanese company Astellas Pharma Inc is developing the DNA vaccine for the pollinosis that is due to Japanese red cedar. The DNA vaccine is in the phase II trials.
A full report of Japan DNA Vaccine Market available @ https://www.omrglobal.com/industry-reports/japan-dna-vaccines-market
Japan DNA Vaccine Market Segmentation
By Type
- Animal DNA Vaccine
- Human DNA Vaccine
By Technology
- Plasmid DNA Vaccine
- Plasmid DNA Delivery
By Application
- Oncology
- Infectious Disease
- Others
Company Profiles
- Asteel Pharma, Inc
- Eli Lilly and Co.
- GE Healthcare
- Glaxosmithkline PLC.
- Inovio Pharmaceuticals Inc.
- Merck & Co.
- Novartis AG
- Pfizer Inc.
- Roche Diagnostics GMBH
- Sanofi Inc.
